Allarity Therapeutics (ALLR)
0.87
+0.02 (2.35%)
Upcoming Events
Latest Headlines
Form 4 Allarity Therapeutics, For: Jan 22 Filed by: Graff Jeremy R.
October 9, 2026 5:13 PM - SEC Filing
Form 8-K Allarity Therapeutics, For: Sep 30
October 1, 2026 8:00 AM - SEC Filing
Allarity updates DRP technology with new patents and lab certification
September 30, 2026 9:00 AM - StreetInsider
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
September 30, 2026 9:00 AM - StreetInsider
Form 8-K Allarity Therapeutics, For: Sep 28
September 29, 2026 8:01 AM - SEC Filing
Allarity adds proteomics and cell line research to its laboratory
September 28, 2026 8:01 AM - StreetInsider
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
September 28, 2026 8:00 AM - Globe NewsWire
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
September 28, 2026 8:00 AM - StreetInsider
Form 8-K Allarity Therapeutics, For: Sep 15
September 16, 2026 8:00 AM - SEC Filing
Allarity wins Japanese patent for stenoparib diagnostic tool
September 15, 2026 8:03 AM - StreetInsider
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
September 15, 2026 8:00 AM - StreetInsider
Form 8-K Allarity Therapeutics, For: Sep 11
September 14, 2026 12:14 PM - SEC Filing
Allarity Therapeutics files SPAC registration for $100M IPO
September 11, 2026 8:01 AM - StreetInsider
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
September 11, 2026 8:00 AM - Globe NewsWire
Form 8-K Allarity Therapeutics, For: Aug 14
August 14, 2026 4:39 PM - SEC Filing
Form 10-Q Allarity Therapeutics, For: Jun 30
August 14, 2026 8:03 AM - SEC Filing
Allarity reports Q2 2026 results, completes stenoparib manufacturing
August 14, 2026 8:00 AM - StreetInsider
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
August 14, 2026 8:00 AM - StreetInsider
Full Article List
